The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete. | |||||||||||||||||
|
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 13F FORM 13F INFORMATION TABLE |
|
||||||||||||||||
| COLUMN 1 | COLUMN 2 | COLUMN 3 | COLUMN 4 | COLUMN 5 | COLUMN 6 | COLUMN 7 | COLUMN 8 | ||||
| VALUE | SHRS OR | SH/ | PUT/ | INVESTMENT | OTHER | VOTING AUTHORITY | |||||
| NAME OF ISSUER | TITLE OF CLASS | CUSIP | (x$1000) | PRN AMT | PRN | CALL | DISCRETION | MANAGER | SOLE | SHARED | NONE |
| Aclaris therapeutics | Common | 00461U105 | 89,116 | 3,283,569 | SH | SOLE | 0 | 0 | 3,283,569 | ||
| Advanced Accelerator Applications S.A. | Common | 00790T100 | 12,197 | 455,798 | SH | SOLE | 0 | 0 | 455,798 | ||
| Agile Therapeutics, Inc. | Common | 00847L100 | 8,630 | 1,513,975 | SH | SOLE | 0 | 0 | 1,513,975 | ||
| Aimmune Therapeutics, Inc. | Common | 00900T107 | 15,604 | 763,009 | SH | SOLE | 0 | 0 | 763,009 | ||
| Akari Therapeutics Plc | ADR | 00972G108 | 3,716 | 527,842 | SH | SOLE | 0 | 0 | 527,842 | ||
| Ascendis Pharma | ADR | 04351P101 | 35,761 | 1,766,832 | SH | SOLE | 0 | 0 | 1,766,832 | ||
| BioPharmX Corporation | Common | 09072X101 | 4,793 | 12,814,286 | SH | SOLE | 0 | 0 | 12,814,286 | ||
| Capnia, Inc. | Common | 14066L105 | 6,040 | 7,456,984 | SH | SOLE | 7,456,984 | 0 | 0 | ||
| Capnia, Inc. | Warrant | 14066L113 | 76 | 943,858 | SH | SOLE | 943,858 | 0 | 0 | ||
| KalVista Pharmaceuticals, Inc. | Common | 483497103 | 2,123 | 300,325 | SH | SOLE | 300,325 | 0 | 0 | ||
| CoLucid Pharmaceuticals, Inc. | Common | 19716T101 | 8,190 | 225,000 | SH | SOLE | 0 | 0 | 225,000 | ||
| Codexis, Inc. | Common | 192005106 | 24,356 | 5,294,825 | SH | SOLE | 0 | 0 | 5,294,825 | ||
| Dynavax Technologies Corporation | Common | 268158201 | 1,421 | 359,828 | SH | SOLE | 0 | 0 | 359,828 | ||
| Eiger BioPharmaceuticals | Common | 28249U105 | 20,820 | 1,787,091 | SH | SOLE | 1,787,091 | 0 | 0 | ||
| Foamix Pharmaceuticals Ltd. | Common | M46135105 | 9,491 | 855,000 | SH | SOLE | 0 | 0 | 855,000 | ||
| Nabriva Therapeutics AG | ADR | 62957M104 | 23,968 | 4,021,559 | SH | SOLE | 0 | 0 | 4,021,559 | ||
| Ocera Therapeutics, Inc. | Common | 67552A108 | 322 | 153,331 | SH | SOLE | 0 | 0 | 153,331 | ||
| ProNAi Therapeutics, Inc. | Common | 74346L101 | 3,633 | 2,438,270 | SH | SOLE | 0 | 0 | 2,438,270 | ||
| Regenxbio Inc. | Common | 75901B107 | 9,328 | 502,863 | SH | SOLE | 0 | 0 | 502,863 | ||
| ReVance Therapeutics, Inc. | Common | 761330109 | 1,602 | 77,373 | SH | SOLE | 0 | 0 | 77,373 | ||
| Strongbridge Biopharma plc | Ordinary Shares | G85347105 | 7,200 | 3,000,000 | SH | SOLE | 0 | 0 | 3,000,000 | ||
| Sunesis Pharmaceuticals, Inc. | Common | 867328700 | 1,810 | 500,000 | SH | SOLE | 0 | 0 | 500,000 | ||
| Trevena, Inc. | Common | 89532E109 | 10,161 | 1,728,000 | SH | SOLE | 0 | 0 | 1,728,000 | ||
| Zosano Pharma Corp | Common | 98979H103 | 77 | 98,515 | SH | SOLE | 0 | 0 | 98,515 | ||
| CRISPR Therapeutics AG | Common | H17182108 | 3,016 | 148,878 | SH | SOLE | 0 | 0 | 148,878 | ||